title: Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.
abstract: Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson's disease (PD).
  
  
  
  We performed a retrospective case-control analysis. First, we identified 2322 incident PD cases having a minimum of 2.5 years of continuous enrollment prior to earliest diagnosis code or prescription of antiparkinson medication. A total of 2322 controls were then matched individually by age, gender, and a follow-up window to explore the relationship of statin use with incident PD.
  
  
  
  Statin usage was significantly associated with PD risk, with the strongest associations being for lipophilic (odds ratio = 1.58, P < .0001) versus hydrophilic (odds ratio = 1.19, P = .25) statins, statins plus nonstatins (odds ratio = 1.95, P < .0001), and for the initial period after starting statins (<1 year odds ratio = 1.82, 1-2.5 years odds ratio = 1.75, and ≥2.5 years odds ratio = 1.37; Ptrend< .0001).
  
  
  
  The use of statin (especially lipophilics) was associated with higher risk of PD, and the stronger association in initial use suggests a facilitating effect. © 2017 International Parkinson and Movement Disorder Society.
authors.affiliation: Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
authors.forename: Guodong
authors.initials: G
authors.lastname: Liu
authors.affiliation: Department of Neurology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
authors.forename: Nicholas W
authors.initials: NW
authors.lastname: Sterling
authors.affiliation: Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
authors.forename: Lan
authors.initials: L
authors.lastname: Kong
authors.affiliation: Department of Neurology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.|Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
authors.forename: Mechelle M
authors.initials: MM
authors.lastname: Lewis
authors.affiliation: Department of Neurology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.|Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
authors.forename: Richard B
authors.initials: RB
authors.lastname: Mailman
authors.affiliation: Department of Epidemiology, Michigan State University, East Lansing, Michigan, USA.
authors.forename: Honglei
authors.initials: H
authors.lastname: Chen
authors.affiliation: Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
authors.forename: Douglas
authors.initials: D
authors.lastname: Leslie
authors.affiliation: Department of Neurology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.|Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
authors.forename: Xuemei
authors.initials: X
authors.lastname: Huang
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D016208:Databases, Factual; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000145:classification; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000453:epidemiology / Q000209:etiology*; D010302:Parkinson Disease, Secondary / Q000453:epidemiology / Q000209:etiology; D012189:Retrospective Studies; D014481:United States / Q000453:epidemiology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Parkinson's disease; cholesterol; large data; statins